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Comment on: Evaluation of adjunctive
mycophenolate for large vessel giant cell arteritis
DEAR EDITOR, We have read the paper by Karabayas
et al. [1] with great interest. The authors should be com-
mended on their work for introducing a new drug, be-
sides glucocorticoids, to the argument about the role of
immunosuppression. As the authors hope, we too feel
that this work will lead to a formal clinical trial for the
role of MMF for the treatment of GCA.
GCA is large vessel vasculitis, and we think that the
authors might be indicating involvement of the immedi-
ate branches of the aorta, including subclavian and axil-
lary arterial involvement, when they term their subset as
having ‘large vessel GCA’; a tautology, because there is
no other type of GCA. The authors have made an ele-
gant biological argument for considering mycophenolic
acid derivatives, but we would be grateful for their
thoughts on the following points.
1. Do the authors feel that involvement of different clus-
ters of arteries is beyond being a phenotype of dis-
ease? If they make an argument for separate clinical
trials for this phenotype, is it because they feel that
this is not only a phenotypical difference, but also a
mechanistic one? In that case, when a patient with
GCA has both cranial and aortic branch involvement
should we classify them as suffering from two dis-
eases that might require different approaches?
2. GCA is a disease of the (relatively) elderly, often with
multiple co-morbidities and risk of polypharmacy.
The selection of medication for managing GCA with-
out any published evidence might have needed
negotiations regionally or nationally to allow the use
of potent immunosuppressive agents, such as
mycophenolic acid derivatives, outside of a clinical
trial, especially in view of its expense before generic
products were available in 2011 [2]. We would be
grateful for any insight that the authors will have
gained from that process to assist the British
Rheumatology community negotiations with similar
perennial discussions.
3. On a related note, there is published evidence and
international consensus for the use of MTX in GCA
[3–5]. We would value the thoughts of the authors on
where they would put MTX in the management of their
patients in the context of the findings of their paper.
4. For a population that was not supposed to have cra-
nial involvement, the authors report a large number of
patients who had cranial symptoms (62% had head-
ache and 24% had visual symptoms). Are they satis-
fied that cranial involvement was satisfactorily ruled
out without resort to temporal artery biopsy or
ultrasonography?
5. Do the authors plan to extend their use to patients
who might also have involvement of cranial arteries?
Once again, we thank the authors for sharing their
work with this journal and its open access platform that
allows for dissemination of scientific information freely.
We look forward to their reply.
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